clinical trial · NCT05475184
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Ovarian CancerJPI-547
brief summary
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
started
Aug 31, 2022
primary completion
Nov 1, 2024
completion
Jun 1, 2025
last updated
Aug 27, 2024
official title
A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol